Compare GSK plc (GSK) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Quantum Computing Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: GSK plc is far larger — about 54.4× Quantum Computing Inc's market cap, and GSK plc pays a 3.9% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Quantum Computing Inc for 25 Days on average.
| GSK | QUBT | |
|---|---|---|
Market Cap | $91.88B | $1.69B |
Volume | 7,730,529 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $61.18 | $21.78 |
52-Week Low | $43.24 | $6.31 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $111.88B | $753.24M |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Quantum Computing Inc. (QUBT) trades at $7.44, down 2.36% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation pose challenges.
QUBT offers significant upside potential with a consensus price target of $17.33 (133% upside) and 75% analyst buy ratings, supported by strong revenue growth and technological advancements. However, the stock carries high risk due to persistent losses, negative cash flow from operations, and execution challenges in the competitive quantum computing space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
